This review article consolidates 21 studies and nearly 16,000 patients to establish outcomes regarding the durability of bioprostheses in the mitral position.

This retrospective study reports on the experience with 15 patients presenting extensive mitral annular calcification (MAC), where a technique utilizing the Cavitron® ultrasonic surgical aspirator (CUSA) was applied during mitral valve replacement procedures.

The STS/ACC TVT registry analysis compares outcomes for patients undergoing TAVI based on whether they receive treatment on a native valve or a previous percutaneous prosthesis (valve-in-valve).

A prospective registry of a large cohort investigating the correlation between the need for aortic valve replacement and cardiorespiratory fitness along with physical activity.

This retrospective single-center study evaluates the relationship between anatomical or non-anatomical disc orientation in mechanical mitral prostheses and the development of pannus.

This single-center study examines the role of the MELD scoring system, traditionally applied to advanced liver disease, in assessing surgical risk for isolated tricuspid valve surgery. This study contrasts MELD with conventional risk scoring systems, such as EuroSCORE II and STS score.

This single-center, retrospective American study evaluates outcomes of prosthesis choice in patients with advanced renal disease on dialysis.

Definition of Framework Criteria of the Valve Academic Research Consortium for Characterizing Tricuspid Regurgitation and Setting Outcomes in Subsequent Studies on Its Invasive Treatment

A retrospective study from two European centers with extensive experience using Edwards Intuity® bioprostheses comparing their perioperative and five-year outcomes with the Carpentier Edwards Magna Ease® bioprosthesis in combined aortic valve replacement and coronary artery bypass grafting (CABG).

An update on outcomes and impressions from the recent TCT Congress in San Francisco on studies examining TAVI vs. surgical aortic valve replacement in low-risk patients: PARTNER 3, Evolut-Low Risk, and NOTION.